Daclatasvir A Hepatitis C Virus Inhibitor

Dacarbavir Indications and uses: DAKLINZA Dacarbazepine is a hepatitis C virus (HCV) NS5A inhibitor suitable for use with sufibrofen [sofosbuvir] for the treatment of chronic HCV genotype 3 infection.

Dosage forms and specifications

Table: 60 mg daclatasvir (equal to 66 mg daclatasvir dihydrochloride), light green, biconvex, pentagonal, and one side depressed with "BMS" and the other side "215".

Table: 30 mg daclatasvir (equal to 33 mg daclatasvir dihydrochloride), green, biconvex, pentagonal, and one side depressed with "BMS" and the other side "213".

Dosage and administration methods

Recommended dose: DAKLINZA recommended dose is 60mg, oral, once a day with the combination of sofloxacin for 12 weeks. DAKLINZA may or may not be taken.

Due to drug interactions Dose Modification: Cytochrome P450 Enzyme 3A, CYP3A Strong Inhibitors: Reduces DAKLINZA Dosage to 30mg once a day When combined with strong CYP3A inhibitors with 30mg tablets.

Moderate CYP3A Inducer: When combined with moderate CYP3A inducer increased DAKLINZA dose to 90 mg 1 day using the appropriate tablet combination (3 tablets 30 mg tablet or 60 mg tablet and 30 mg tablet).

Strong CYP3A Inducer: DAKLINZA is contraindicated with strong CYP3A inducers.

Recommendations for adverse reactions do not reduce DAKLINZA dose.

The termination of treatment

One patient who received DAKLINZA and sofloxacin permanently terminated sofloxacin, and then DAKLINZA should also be terminated.


DAKLINZA is contraindicated with a strong induction of CYP3A drug combination, which may lead to lower exposure to DAKLINZA and loss of efficacy. Taboo drugs include: phenytoin, carbamazepine, rifampin, and St. John's wort.

Warnings and cautions

Bradycardia when administered in combination with sufiboxibir and amiodarone: A severe symptomatic bradycardia may occur in patients taking amiodarone and sofloxacin in combination with another HCV direct drug, including DAKLINZA (daclatasvir ), In particular, beta-blockers or those with potential cardiac complications and advanced liver disease. It is suggested that amiodarone should not be administered in combination with DAKLINZA and sofloxacin.